使用基于蛋白质的纳米粒子药物递送系统治疗炎症性肠病的口服治疗方面取得了进展
Zhihao Lin1,2, Ziheng Zhao1,3, Xianrui Lin1,2
1State Key Laboratory of Resource Insects, Southwest University, Chongqing, China.
Drug delivery
|August 12, 2025
概括
基于蛋白质的纳米颗粒药物递送系统 (PNP-DDS) 显示出对治疗炎症性肠病 (IBD) 的前景,通过向结肠提供有针对性的药物递送. 需要进一步的创新,以确保这些先进疗法的安全和有效的临床转化.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 需要先进的,由于显著的发病率,非侵入性疗法.
- 传统的IBD治疗在药物稳定性,生物可用性和向性治疗方面存在局限性.
- 基于蛋白质的纳米粒子药物递送系统 (PNP-DDS) 为IBD管理提供了一个有前途的替代方案.
研究的目的:
- 系统地审查基于蛋白质的纳米粒子药物递送系统 (PNP-DDS) 对于炎症性肠病 (IBD).
- 讨论PNP-DDS的设计原则和肠道向策略.
- 要突出临床前进展和挑战在临床翻译PNP-DDS的IBD.
主要方法:
- 从天然蛋白质 (白蛋白,凝,丝纤维蛋白,植物蛋白) 中衍生出来的PNP-DDS的系统分类.
- 对肠道向策略的分析:粒子大小,表面电荷,刺激反应释放 (pH,ROS,酶) 和主动向.
- 在IBD模型中使用口服PNP-DDS与抗炎药物 (黄素,白醇,5-ASA,氨酸) 的临床前研究的综述.
主要成果:
- PNP-DDS证明改善了药物稳定性,生物可用性和IBD治疗的结肠特异性输送.
- 可以利用各种天然蛋白质来构建有效的PNP-DDS.
- 临床前研究表明,在IBD模型中,口服PNP-DDS具有显著的治疗潜力.
结论:
- PNP-DDS为向IBD治疗提供了一个有前途的纳米平台.
- 在临床转化方面仍然存在挑战,包括患者异质性,制造和安全性.
- 未来的研究应该专注于跨学科的创新和多刺激响应设计,以准确的临床应用.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
01:29Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420